Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

$96m RNA Research and Manufacturing Facility opens in NSW

The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...

Cartherics and Catalent announce enhanced partnership

To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...

Alliance seeks to boost regional capacity in clinical trials

Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...

Content from other channels on our network

As AI reshapes health care, human skills are more important than ever

Optometry Australia to unify into single national entity

NSW announces review into 'stranded' aged care patients

PASA Health & Aged Care Procurement Conference returns in June

Why Some People Thrive in High-Energy Environments, and Others Need to Stay Calm

Alfa Laval hosts academic event in food engineering

Food ingredient plant implements an electrification strategy

Imperfect plums repurposed into new food products

Distillery cuts energy bills by 80%

Young viticulturists in NZ start preparing for 2026 competitions

Coca-Cola Europacific Partners leads Pacific PET circularity program

Adversaries leveraging public AI tools to target OT systems

ABB Robotics launches automated surface finishing cell

Siemens expands digital water solutions

Government announces expanded minerals cooperation with Japan